Global Bladder Cancer Market 2022-2028

Global Bladder Cancer Market 2022-2028

The global bladder cancer market is growing at a significant CAGR of 5.2% during the forecast period (2022-2028). The market is increasing due to the consumption of tobacco, and smoking, past harmful radiation experiences, parasitic infections, and certain changes in the genes that are linked to bladder cancer. Past treatment with radiation therapy or certain anticancer drugs, such as cyclophosphamide or ifosfamide cause bladder cancer, which are further driving the growth of the market. Additionally, continuous innovation in drug development and technological advancement in different therapies such as immunotherapy and chemotherapy are expected to drive the growth of the global bladder cancer market. The firms present in the market are engrossed in evolving innovative diagnostic and treatment solutions for bladder cancer. For instance, In January 2020, Merck & Co., Inc. received the US FDA approval for pembrolizumab a product that can be used as an alternative to radical surgery in certain bladder cancer patients.Moreover, growing health care expenditures are likely to drive the bladder cancer market across the globe. However, the increase in the number of drug patent terminations, the rise in the use of generic drugs, the asymptomatic nature of the disease, the high costs of therapies, and inaccurate and unaffordable diagnosis are the restraining factors of the global market.

Impact of COVID-19 on the Bladder Cancer Market

The global bladder cancer market significantly affected by the COVID-19 pandemic since December 2019, The COVID-19 pandemic has increased by waiting times for cystoscopies and raise concerns of deferred diagnoses and inferior surveillance of bladder cancer. To overcome this pandemic the company’s expanding the role of urinary biomarkers in diagnostic and surveillance pathways could be a strategy to address this problem.

Segmental Outlook

The market is segmented based on cancer type, diagnosis method, and therapy. Based on cancer type, the market is segmented into transitional cell bladder cancer/urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, other rare types (sarcomas, carcinoma in situ). By diagnosis method, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on therapy, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, others.

The transitional cell bladder cancer segment projected to dominate the global bladder cancer market

Among cancer types, the transitional cell bladder cancer/ urothelial carcinoma segment holds the largest market share in the global bladder cancer market. The growth of the segment is attributed to the fact that transitional cell bladder cancer/urothelial carcinoma is the most common type of bladder cancer having more prevalence than any other type of bladder cancer. Urothelial carcinoma is a malignant neoplasm happening from the urothelium. The syndrome is one of the ninth most common malignancies across the globe, with around 2.5 million patients, and 420,000 newly diagnosed cases each year. Bladder transitional cell carcinoma (TCC) accounted for about 90% of all urinary cancer cases.

Regional Outlook

The global bladder cancer market is analyzed on the basis of the geographical regions that are contributing significantly to the growth of the market. The market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific) and Rest of the World (RoW). North America is estimated to contribute a significant share in the global bladder cancer market.The growth of the region is attributed to high healthcare expenditure, increasing prevalence of bladder cancer coupled with the surging geriatric population, and the presence of major market players in the region.

Market Players Outlook

Further, the report covers the analysis of various players operating in the global bladder cancer market, Some of the major players covered in the report include Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Bristol-Myers Squibb Co., AstraZeneca Plc, Merck KGaA, and others. To sustain a strong position in the market, these players adopt different marketing strategies such as a merger, acquisitions, product launches, and geographical expansion. For instance, In September 2020, Bristol-Myers Squibb received the USFDA Approval for Opdivo (nivolumab) in Previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. In April 2020, Merck KGaA, and Pfizer Inc. the biopharmaceutical company received the US (FDA) Food and Drug Administration approval for BAVENCIO. That can be used for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC).

The Report Covers

Market value data analysis of 2021 and forecast to 2028.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global bladder cancer market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.